A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy

J Med Chem. 2000 Apr 6;43(7):1253-6. doi: 10.1021/jm9905864.
No abstract available

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / metabolism
  • Antineoplastic Agents / pharmacology*
  • Carcinoma, Renal Cell / drug therapy
  • Carcinoma, Renal Cell / pathology
  • Chromatography, High Pressure Liquid
  • Cysteine / metabolism
  • Doxorubicin / administration & dosage*
  • Doxorubicin / analogs & derivatives
  • Doxorubicin / metabolism
  • Doxorubicin / pharmacology*
  • Drug Screening Assays, Antitumor
  • Humans
  • Hydrazones / administration & dosage
  • Hydrazones / chemical synthesis*
  • Hydrazones / metabolism
  • Hydrazones / pharmacology*
  • In Vitro Techniques
  • Kidney Neoplasms / drug therapy
  • Kidney Neoplasms / pathology
  • Mice
  • Mice, Inbred BALB C
  • Neoplasm Transplantation
  • Prodrugs / administration & dosage
  • Prodrugs / metabolism
  • Prodrugs / pharmacology*
  • Protein Binding
  • Serum Albumin / metabolism*

Substances

  • Antineoplastic Agents
  • Hydrazones
  • Prodrugs
  • Serum Albumin
  • doxorubicin 4-(maleimid-1-yl)phenylacetylhydrazone
  • Doxorubicin
  • Cysteine